Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7 Ethyl 10 Hydroxycamptothecin
2. 7-ethyl-10-hydroxycamptothecin
3. Camptosar
4. Camptothecin 11
5. Camptothecin-11
6. Cpt 11
7. Cpt-11
8. Cpt11
9. Irinotecan
10. Irrinotecan
11. Nk012 Compound
12. Sn 38
13. Sn 38 11
14. Sn-38
15. Sn-38-11
16. Sn3811
1. 100286-90-6
2. Irinotecan Hcl
3. Topotecin
4. Campto
5. Camptothecin 11 Hydrochloride
6. Camptosar
7. Cpt 11
8. Cpt-11
9. Irinotecan (hydrochloride)
10. Camptothecin 11
11. U 101440e
12. Chebi:5971
13. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
14. Camptothecin Analog
15. 06x131e4oe
16. 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy Camptothecin Hydrochloride
17. Nsc616348
18. Nsc-616348
19. Ncgc00095190-01
20. Dsstox_cid_25953
21. Dsstox_rid_81249
22. Dsstox_gsid_45953
23. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride
24. Irinotecan Hydrochloride Anhydrous
25. Cas-100286-90-6
26. U-101440e
27. Unii-06x131e4oe
28. Irinotecan Hydrochloride [usan:jan]
29. Mfcd01862255
30. Irinotecanhydrochloride
31. Cpt-11 Hydrochloride
32. Irinotecan Monohydrochloride
33. Schembl4033
34. Camptosar (tn) (pharmacia)
35. (s)-[1,4'-bipiperidine]-1'-carboxylic Acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester Hydrochloride
36. Spectrum1505821
37. Chembl541887
38. Dtxsid6045953
39. Hms1922j04
40. Pharmakon1600-01505821
41. Amy24895
42. Bcp17234
43. Irinotecan Hydrochloride (anhydrous)
44. Tox21_111479
45. Hy-16562a
46. Nsc759878
47. S5026
48. Akos015901921
49. Tox21_111479_1
50. Ccg-213561
51. Irinotecan Hydrochloride [who-dd]
52. Ncgc00095190-02
53. Ncgc00178697-04
54. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride
55. (1,4'-bipiperidine)-1'-carboxylic Acid, 3,4,12,14-tetrahydro-4,11-diethyl-4-hydroxy-3,4-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride, (s)-
56. Ac-28335
57. As-13304
58. I0714
59. Irinotecan Hydrochloride Anhydrous [mi]
60. Irinotecan Hydrochloride, Topoisomerase Inhibitor
61. 286i906
62. A897508
63. Sr-01000763864
64. Q-100016
65. Sr-01000763864-3
66. Q27106952
67. Z1550648758
68. (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate, Monohydrochloride
69. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Hydrochloride (1:1)
70. (19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
71. (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic Acid Ester Hydrochloride
72. (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
73. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylatehydrochloride
74. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate Hydrochloride
75. [1, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7] Indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride (s)-
76. [1,4'-bipiperidine]-1'-carboxylic Acid,(4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride
77. 1-[1-({[(4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]piperidin-1-ium Chloride
1. Camptosar
2. Campto
3. Irinotecan
4. Hy-16562
Molecular Weight | 623.1 g/mol |
---|---|
Molecular Formula | C33H39ClN4O6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 622.2558127 g/mol |
Monoisotopic Mass | 622.2558127 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 44 |
Formal Charge | 0 |
Complexity | 1200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
2 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-14
Pay. Date : 2013-09-05
DMF Number : 20649
Submission : 2007-06-29
Status : Active
Type : II
Certificate Number : CEP 2017-236 - Rev 02
Issue Date : 2023-09-22
Type : Chemical
Substance Number : 2675
Status : Valid
Registration Number : 220MF10025
Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland
Initial Date of Registration : 2008-01-23
Latest Date of Registration :
NDC Package Code : 12780-4860
Start Marketing Date : 2007-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : TNS
Registration Date : 2022-01-13
Registration Number : 20220113-210-J-1177
Manufacturer Name : Fermion Oy
Manufacturer Address : Laaketehtaantie 2, Oulu, FI-90660, Finland
Available Reg Filing : CN |
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Certificate Number : CEP 2023-338 - Rev 00
Issue Date : 2025-05-13
Type : Chemical
Substance Number : 2675
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17312
Submission : 2004-04-20
Status : Active
Type : II
Certificate Number : CEP 2017-163 - Rev 01
Issue Date : 2024-09-11
Type : Chemical
Substance Number : 2675
Status : Valid
Registration Number : 303MF10140
Registrant's Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 741014, Taiwan
Initial Date of Registration : 2021-09-02
Latest Date of Registration :
NDC Package Code : 65129-1025
Start Marketing Date : 2003-07-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hiple Co., Ltd.
Registration Date : 2023-06-30
Registration Number : 20230630-210-J-1513
Manufacturer Name : ScinoPharm Taiwan, Ltd.
Manufacturer Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 74144, Taiwan
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21183
Submission : 2007-12-25
Status : Active
Type : II
Registration Number : 218MF10990
Registrant's Address : No. 1, Nan-Ke 8th Road, Shan-Hua, Tainan 74144, Taiwan
Initial Date of Registration : 2006-12-18
Latest Date of Registration :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-09
Pay. Date : 2012-12-18
DMF Number : 23562
Submission : 2010-02-23
Status : Active
Type : II
Certificate Number : R1-CEP 2017-147 - Rev 00
Issue Date : 2023-07-04
Type : Chemical
Substance Number : 2675
Status : Valid
NDC Package Code : 82920-702
Start Marketing Date : 2022-08-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2021-11-23
Registration Number : 20210210-210-J-700(1)
Manufacturer Name : Shilpa Medicare Limited, Unit-1
Manufacturer Address : 1A & 1A'P', 1B, 2, 2A, 2B, 3A to 3E, 4A, 5A, 4B & 5B , Deosugur Industrial area, Deosugur, Raichur - 584 170, Karnataka, India
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-06-01
Pay. Date : 2015-05-22
DMF Number : 24133
Submission : 2010-08-19
Status : Active
Type : II
Certificate Number : CEP 2016-276 - Rev 01
Issue Date : 2024-06-26
Type : Chemical
Substance Number : 2675
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-21
Pay. Date : 2018-11-16
DMF Number : 21713
Submission : 2008-06-10
Status : Active
Type : II
Certificate Number : R1-CEP 2017-096 - Rev 00
Issue Date : 2023-04-24
Type : Chemical
Substance Number : 2675
Status : Valid
NDC Package Code : 61200-112
Start Marketing Date : 2015-05-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER, FOR SUSPENSION (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21272
Submission : 2008-01-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8553
Submission : 1990-05-02
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2008-11-21
Application Number : 79068
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2008-02-27
Application Number : 78589
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2010-04-15
Application Number : 78953
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2009-09-16
Application Number : 90726
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2019-11-18
Application Number : 212993
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2010-12-20
Application Number : 91032
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 2010-12-20
Application Number : 91032
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 40MG/2ML (20MG/ML)
Approval Date : 2008-02-27
Application Number : 77915
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : Yes
TE Code : AP
Brand Name : CAMPTOSAR
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 100MG/5ML (20MG/ML)
Approval Date : 1996-06-14
Application Number : 20571
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP
RLD : No
TE Code : AP
Brand Name : IRINOTECAN HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 300MG/15ML (20MG/ML)
Approval Date : 2016-05-03
Application Number : 203380
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
Regulatory Info :
Registration Country : Norway
Brand Name : Irinotecan Actavis
Dosage Form : Concentrate to the infusion fluid
Dosage Strength : 20 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : Irinotecan
Dosage Form : Irinotecan 100Mg 5Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 100 mg 5 ml 20 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
Brand Name : Irinotecan Kabi
Dosage Form : CONCENTRATE FOR SOLUTION FOR INFUSION
Dosage Strength : 20 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Irinotecan The Fresenius Kabi
Dosage Form : Concentrate to the infusion fluid, resolution
Dosage Strength : 20 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Irinotecani Hydrochloridum Trihydricum
Brand Name : Irinotecan Labatec
Dosage Form : Inf Conc
Dosage Strength : 100mg/5ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Irinotecani Hydrochloridum Trihydricum
Brand Name : Campto
Dosage Form : Inf Konz
Dosage Strength : 40mg/2ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : Irinotecan
Dosage Form : Irinotecan 300Mg 15Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 300 mg 15 ml 20 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Irinotecan
Dosage Form : Irinotecan 40Mg 2Ml 5 Units Parenteral Use
Dosage Strength : 5 VIALS EV 40 mg 2 ml 20 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Generic
Registration Country : United Kingdom
Brand Name :
Dosage Form : SOLUTION
Dosage Strength : 500MG/25ML
Packaging : Vial
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : United Kingdom
Regulatory Info :
Registration Country : Italy
Brand Name : Irinotecan
Dosage Form : Irinotecan 500Mg 25Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 500 mg 25 ml 20 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
58
PharmaCompass offers a list of Irinotecan Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier.
PharmaCompass also assists you with knowing the Irinotecan Hydrochloride API Price utilized in the formulation of products. Irinotecan Hydrochloride API Price is not always fixed or binding as the Irinotecan Hydrochloride Price is obtained through a variety of data sources. The Irinotecan Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 042LAQ1IIS manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 042LAQ1IIS, including repackagers and relabelers. The FDA regulates 042LAQ1IIS manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 042LAQ1IIS API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 042LAQ1IIS manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 042LAQ1IIS supplier is an individual or a company that provides 042LAQ1IIS active pharmaceutical ingredient (API) or 042LAQ1IIS finished formulations upon request. The 042LAQ1IIS suppliers may include 042LAQ1IIS API manufacturers, exporters, distributors and traders.
click here to find a list of 042LAQ1IIS suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 042LAQ1IIS DMF (Drug Master File) is a document detailing the whole manufacturing process of 042LAQ1IIS active pharmaceutical ingredient (API) in detail. Different forms of 042LAQ1IIS DMFs exist exist since differing nations have different regulations, such as 042LAQ1IIS USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 042LAQ1IIS DMF submitted to regulatory agencies in the US is known as a USDMF. 042LAQ1IIS USDMF includes data on 042LAQ1IIS's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 042LAQ1IIS USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 042LAQ1IIS suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The 042LAQ1IIS Drug Master File in Japan (042LAQ1IIS JDMF) empowers 042LAQ1IIS API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the 042LAQ1IIS JDMF during the approval evaluation for pharmaceutical products. At the time of 042LAQ1IIS JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of 042LAQ1IIS suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 042LAQ1IIS Drug Master File in Korea (042LAQ1IIS KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 042LAQ1IIS. The MFDS reviews the 042LAQ1IIS KDMF as part of the drug registration process and uses the information provided in the 042LAQ1IIS KDMF to evaluate the safety and efficacy of the drug.
After submitting a 042LAQ1IIS KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 042LAQ1IIS API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 042LAQ1IIS suppliers with KDMF on PharmaCompass.
A 042LAQ1IIS CEP of the European Pharmacopoeia monograph is often referred to as a 042LAQ1IIS Certificate of Suitability (COS). The purpose of a 042LAQ1IIS CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 042LAQ1IIS EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 042LAQ1IIS to their clients by showing that a 042LAQ1IIS CEP has been issued for it. The manufacturer submits a 042LAQ1IIS CEP (COS) as part of the market authorization procedure, and it takes on the role of a 042LAQ1IIS CEP holder for the record. Additionally, the data presented in the 042LAQ1IIS CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 042LAQ1IIS DMF.
A 042LAQ1IIS CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 042LAQ1IIS CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 042LAQ1IIS suppliers with CEP (COS) on PharmaCompass.
A 042LAQ1IIS written confirmation (042LAQ1IIS WC) is an official document issued by a regulatory agency to a 042LAQ1IIS manufacturer, verifying that the manufacturing facility of a 042LAQ1IIS active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 042LAQ1IIS APIs or 042LAQ1IIS finished pharmaceutical products to another nation, regulatory agencies frequently require a 042LAQ1IIS WC (written confirmation) as part of the regulatory process.
click here to find a list of 042LAQ1IIS suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 042LAQ1IIS as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 042LAQ1IIS API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 042LAQ1IIS as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 042LAQ1IIS and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 042LAQ1IIS NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 042LAQ1IIS suppliers with NDC on PharmaCompass.
042LAQ1IIS Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 042LAQ1IIS GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 042LAQ1IIS GMP manufacturer or 042LAQ1IIS GMP API supplier for your needs.
A 042LAQ1IIS CoA (Certificate of Analysis) is a formal document that attests to 042LAQ1IIS's compliance with 042LAQ1IIS specifications and serves as a tool for batch-level quality control.
042LAQ1IIS CoA mostly includes findings from lab analyses of a specific batch. For each 042LAQ1IIS CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
042LAQ1IIS may be tested according to a variety of international standards, such as European Pharmacopoeia (042LAQ1IIS EP), 042LAQ1IIS JP (Japanese Pharmacopeia) and the US Pharmacopoeia (042LAQ1IIS USP).